Menu Search
Equities

ImmuCell Corp

ICCC:NAQ

ImmuCell Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.69
  • Today's Change0.06 / 1.65%
  • Shares traded316.00
  • 1 Year change-29.71%
  • Beta0.5656
Data delayed at least 15 minutes, as of Sep 20 2024 14:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year ImmuCell Corp's revenues fell -5.90% from 18.57m to 17.47m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a loss of 2.49m to a larger loss of 5.77m.
Gross margin26.05%
Net profit margin-17.44%
Operating margin-15.11%
Return on assets-9.43%
Return on equity-16.10%
Return on investment-10.50%
More ▼

Cash flow in USDView more

In 2023, cash reserves at ImmuCell Corp fell by 4.81m. Cash Flow from Financing totalled 1.75m or 10.02% of revenues. In addition the company used 4.67m for operations while cash used for investing totalled 1.89m.
Cash flow per share-0.172
Price/Cash flow per share--
Book value per share2.99
Tangible book value per share2.98
More ▼

Balance sheet in USDView more

ImmuCell Corp has a Debt to Total Capital ratio of 32.43%, unchanged from the previous year.
Current ratio2.37
Quick ratio0.7668
Total debt/total equity0.48
Total debt/total capital0.3243
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.